Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

Burning Rock Biotech (BNR) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Burning Rock Biotech (BNR) over the last 6 years, with Q3 2025 value amounting to 14.05%.

  • Burning Rock Biotech's EBITDA Margin rose 169000.0% to 14.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 21.61%, marking a year-over-year increase of 630000.0%. This contributed to the annual value of 66.53% for FY2024, which is 543200.0% up from last year.
  • Burning Rock Biotech's EBITDA Margin amounted to 14.05% in Q3 2025, which was up 169000.0% from 6.69% recorded in Q2 2025.
  • In the past 5 years, Burning Rock Biotech's EBITDA Margin registered a high of 6.69% during Q2 2025, and its lowest value of 195.13% during Q1 2022.
  • Its 5-year average for EBITDA Margin is 110.69%, with a median of 133.96% in 2023.
  • As far as peak fluctuations go, Burning Rock Biotech's EBITDA Margin tumbled by -1189000bps in 2021, and later skyrocketed by 1077400bps in 2024.
  • Quarter analysis of 5 years shows Burning Rock Biotech's EBITDA Margin stood at 187.22% in 2021, then increased by 17bps to 156.21% in 2022, then grew by 13bps to 136.47% in 2023, then surged by 56bps to 59.74% in 2024, then soared by 76bps to 14.05% in 2025.
  • Its last three reported values are 14.05% in Q3 2025, 6.69% for Q2 2025, and 10.21% during Q1 2025.